Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 4/20 | 0.56 |
| ▸ | DRD2 | P14416 | 2/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.54 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | SLC18A3 | Q16572 | 4/20 | 0.52 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.51 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.50 |
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11558282 | 0.87 | FUCA1 (0.60) | KDM1ADRD2MAOBHTTSLC18A3 | |
| SCHEMBL11558271 | 0.87 | FUCA1 (0.60) | KDM1ADRD2MAOBHTTSLC18A3 | |
| SCHEMBL11558275 | 0.87 | FUCA1 (0.60) | KDM1ADRD2MAOBHTTSLC18A3 | |
| SCHEMBL6042186 | 0.86 | KDM1A (0.55) | KDM1ADRD2HTTSLC18A3FUCA1 | |
| SCHEMBL6042249 | 0.85 | ACHE (0.56) | DRD2HTTSLC18A3FUCA1ALDH1A1 | |
| SCHEMBL6041900 | 0.84 | ACHE (0.55) | HTTSLC18A3FUCA1ALDH1A1 | |
| SCHEMBL6043310 | 0.84 | FUCA1 (0.53) | HTTSLC18A3FUCA1ALDH1A1 | |
| SCHEMBL6042732 | 0.84 | RORC (0.58) | HTTSLC18A3FUCA1ALDH1A1 | |
| SCHEMBL6041781 | 0.84 | SLC18A3 (0.58) | SLC18A3FUCA1ALDH1A1 | |
| SCHEMBL6043029 | 0.82 | FUCA1 (0.50) | HTTSLC18A3S1PR5FUCA1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060079533-A1 | Methods of treating alzheimer's disease | NIEMAN JAMES A | 2006-04-13 | — | — | US | disclosed |
| WO-2002076440-A2 | METHODS OF TREATING ALZHEIMER'S DISEASE WITH PIPERIDIN DERIVATES | ELAN PHARMACEUTICALS, INC. (US) | 2002-10-03 | — | — | WO | disclosed |
| US-6150526-A | Piperidine derivative having renin inhibiting activity | HOFFMANN-LA ROCHE INC. (US) | 2000-11-21 | — | — | US | disclosed |
| US-6051712-A | PREVENTION OF HIGH BLOOD PRESSURE AND CARDIAC INSUFFICIENCY, AS WELL AS GLAUCOMA, CARDIAC INFARCT, KIDNEY INSUFFICIENCY AND RESTENOSIS | HOFFMANN-LA ROCHE INC. (US) | 2000-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079533-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, PSEN2 | KDM1A 1891/4885DRD2 2550/4885MAOB 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.